Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19 — Zara Izadi (2021) | RDL Network
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19
Article 2021 en
Authors
ZI
Zara Izadi
EB
Erica J. Brenner
SM
Satveer K. Mahil
Abstract
1 min read
In this cohort study, TNF inhibitor monotherapy was associated with a lower risk of adverse COVID-19 outcomes compared with other commonly prescribed immunomodulatory treatment regimens among individuals with IMIDs.
Mark Yates, Sinéad Langan, Zenas Z N Yiu, Teresa Tsakok, Nick Dand, K.J. Mason, Helen McAteer, Freya Meynell, Bola Coker, Alexandra Vincent, Dominic Urmston, A Vesty, J Kelly, Camille Lancelot, Lucy Moorhead, H. Bachelez, Ian N Bruce, Francesca Capon, Claudia Romina Contreras, Andrew P. Cope, Paola Di Meglio, Paolo Gisondi, Kimme L Hyrich, D. Jullien, John S. Lambert, Helena Marzo‐Ortega, Iain B. McInnes, Luigi Naldi, Sam Norton, L. Puig, Raj Sengupta, Phyllis I. Spuls, Tiago Torres, Richard B. Warren, H Waweru, John Weinman, Christopher Em Griffiths, Juliet N. Barker, Matthew A. Brown, James Galloway, Catherine Smith
Giacomo Grasselli, Alberto Zanella, Eleonora Carlesso, Gaetano Florio, Arif Canakoglu, Giacomo Bellani, Nicola Bottino, Luca Cabrini, Gian Paolo Castelli, E Catena, Maurizio Cecconi, Danilo Cereda, Davide Chiumello, Andrea Forastieri, Giuseppe Foti, Marco Gemma, Riccardo Giudici, Lorenzo Grazioli, Andrea Lombardo, Ferdinando Luca Lorini, Fabiana Madotto, Alberto Mantovani,
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.